BLUE - ブル―バ―ド・バイオ (bluebird bio Inc.) ブル―バ―ド・バイオ

 BLUEのチャート


 BLUEの企業情報

symbol BLUE
会社名 bluebird bio Inc (ブル―バ―ド・バイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ブルーバード(bluebird bio Inc.)は臨床開発段階にあるバイオテクノロジー企業であり、重症及び癌の遺伝子治療の開発に集中する。同社はレンチウイルスに基づく遺伝子治療と遺伝子編集機能を通じて、これらの分野におけるさまざまなアプリケーションを備えた統合製品プラットフォームを作成した。同社の複数の遺伝病に対する遺伝子臨床プログラムは輸血依存性β-サラセミアと重症鎌状赤血球病(SCD)を治療するLentiGlobin製品候補、脳性副腎白質ジストロフィー(CALD)を治療するLenti-D製品候補を含む。同社の腫瘍学におけるプログラムはキメラ抗原受容体(CAR) T細胞受容体(TCR)療法を含むT細胞ベースの免疫療法の開発に集中する。同社の腫瘍のリード製品候補bb2121は多発性骨髄腫の治療のためのCAR T細胞産物候補である。同社はパイプラインに応用する可能のメガTAL /ホーミングエンドヌクレアーゼ遺伝子編集技術を利用する発見研究プログラムがある。   ブル―バ―ド・バイオは、米国のバイオ医薬品企業。遺伝性疾患や難病向けに遺伝子治療製品の開発を手掛ける。主要製品候補はレンチDと呼ばれる副腎白質ジストロフィ―の治療薬と、サラセミアおよび鎌状赤血球病治療薬のレンチグロビンである。また、がん治療分野にて、がん細胞を破壊し患者自身のT細胞の遺伝子組換えなどの研究開発を手掛ける。   bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.
本社所在地 60 Binney Street Cambridge MA 02142 USA
代表者氏名 Daniel S. Lynch ダニエルS.リンチ
代表者役職名 Independent Chairman of the Board
電話番号 +1 339-499-9300
設立年月日 33695
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 479人
url www.bluebirdbio.com
nasdaq_url https://www.nasdaq.com/symbol/blue
adr_tso
EBITDA EBITDA(百万ドル) -444.21700
終値(lastsale) 133.44
時価総額(marketcap) 7226832311.04
時価総額 時価総額(百万ドル) 7380.099
売上高 売上高(百万ドル) 35.68700
企業価値(EV) 企業価値(EV)(百万ドル) 6458.457
当期純利益 当期純利益(百万ドル) -351.15500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 bluebird bio Inc revenues increased 1% to $23.8M. Net loss increased 87% to $261.1M. Revenues reflect Collaboration revenue increase of 78% to $23M. Higher net loss reflects Change in fair value of contingent consi increase of 72% to $796K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.41 to -$5.22.

 BLUEのテクニカル分析


 BLUEのニュース

   BLUE Stock Plummets On Clinical Hold, Plans To Exit Europe  2021/08/09 20:24:55 Bitcoin Ethereum News
The post BLUE Stock Plummets On Clinical Hold, Plans To Exit Europe appeared on BitcoinEthereumNews.com . Bluebird Bio (BLUE) said Monday the Food and Drug Administration paused one of its gene therapy studies due to safety concerns, and BLUE stock collapsed. X The drug isnt approved
   Bluebird bio cut to market perform at SVB Leerink; says bullish thesis is untenable"  2021/08/09 19:16:42 Seeking Alpha
   Why Bluebird Bio''s Stock Is Trading Lower Today  2021/08/09 19:09:36 Benzinga
Bluebird Bio Inc (NASDAQ: BLUE ) is trading lower Monday Full story available on Benzinga.com
   SVB Leerink Says ''We Were Wrong,'' Slashes Bluebird Bio Price Target  2021/08/09 17:41:05 Benzinga
Latest Ratings for BLUE Date Firm Action From To Jul 2021 Morgan Full story available on Benzinga.com
   Bluebird Stock Crashes To 7-Year Low After FDA Pauses Gene Therapy Test  2021/08/09 17:14:20 Investor''s Business Daily
Bluebird Bio said Monday the FDA paused one of its gene therapy studies due to safety concerns, and BLUE stock collapsed.
   BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE  2021/06/12 02:50:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE). In May 2020, the Company announced its plans to submit an application to the U.S. Food and Drug Administration (FDA) for its product, LentiGlobin, in the second half of 2021. Then, on November 4, 2020, the Company disclosed that, due to the FDA
   Bluebird Bio (BLUE) Gets a Hold Rating from William Blair  2021/06/11 18:15:31 Smarter Analyst
William Blair analyst Raju Prasad maintained a Hold rating on Bluebird Bio (BLUE) today. The companys shares closed last Friday at $33. The post Bluebird Bio (BLUE) Gets a Hold Rating from William Blair appeared first on Smarter Analyst .
   betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for -thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual  2021/06/11 09:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO in the EU and UK) in adult, adolescent and pediatric patients with transfusion-dependent -thalassemia (TDT). These data were presented during EHA2021 Virtual, the 26th Annual Congress of the European Hematology Association, taking place June 9-17, 2021. Our maturing clinical data continue to deliver the result
   FDA gives OK to Bluebird bio to resume gene therapy trials | WRAL TechWire  2021/06/10 12:54:48 WRAL TechWire
RESEARCH TRIANGLE PARK -Bluebird bio, a gene therapy company with manufacturing facilities in Durham, is resuming clinical trials of potential therapies for two
   Global Adrenoleukodystrophy treatment Trends and Highlights / Applied Genetic Technologies Corporation; Bluebird bio; Magenta Therapeutics.  2021/06/10 12:25:38 OpenPR
Adrenoleukodystrophy (ALD) is a rare genetic condition that causes the buildup of very-long-chain fatty acids (VLCFAs) in the brain. The defective gene in ALD, commonly referred to as a genetic mutation, can cause several different but related conditions: adrenomyelopathy (AMN),
   U.S. Food and Drug Administration Approves Bristol Myers Squibb's and bluebird bio's Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma  2021/03/27 02:59:00 Benzinga
Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma 1 In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses 1 Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution 1 Bristol Myers Squibb (NYSE: BMY ) and bluebird bio, Inc . (NASDAQ: BLUE ) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is a personalized immune cell therapy approved as a one-time infusion with a recommended dose range of 300 to 460 x 10 6 CAR-positive T cells. 1 As an anti-BCMA CAR T cell therapy, Abecma recognizes and binds to BCMA, a protein that is nearly universally expressed on cancer cells in multiple myeloma, leading to the death of BCMA-expressing cells. 2 Please see the Important Safety Information section below, including Boxed WARNINGS for Abecma regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities (NT), Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), and Prolonged Cytopenia.
   BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. - Stocks News Feed  2021/03/22 14:58:00 Stocks News Feed
NEW YORK, March 22, 2021 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of bluebird bio, Inc. (“bluebird”… Read More »BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.
   ROSEN, A LEADING LAW FIRM, Encourages bluebird bio, Inc. Investors with Large Losses to Secure Counsel Before Important April 13 Deadline in Securities Class Action - BLUE  2021/03/20 22:20:00 PR Newswire
NEW YORK, March 20, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of bluebird bio, Inc. (NASDAQ: BLUE) between May 11, 2020 and November 4, 2020, inclusive (the "Class Period") of the important April 13, 2021 lead…
   FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings  2021/03/20 13:52:31 Benzinga
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY ) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors. Marker Therapeutics, Inc. (NASDAQ: MRKR ) had a volatile ride amid an announcement concerning common stock offering and insider buying. The Muscular Dystrophy Association and the Society of Gynecologic Oncology meetings scheduled for the week provided platforms for multiple presentations by companies. Some of the presentations moved stocks in a big way. The week also witnessed listings by four biopharma companies, which raised a cumulative $678.84 million in gross proceeds through initial public offerings. Here are the key catalysts for the unfolding week: Conferences The Endocrine Society's ENDO 2021: March 20-23 PDUFA Dates The Food and Drug Administration is likely to rule on Pacira Biosciences Inc 's (NASDAQ: PCRX ) supplemental new drug application for Exparel as a single-dose postsurgical pain relief treatment for children, aged six and over.
   BLUE INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.  2021/03/18 13:47:00 PR Newswire
NEW YORK, March 18, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ブル―バ―ド・バイオ BLUE bluebird bio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)